
SS-31 ยท 10 mg
A synthetic four-amino-acid peptide that crosses into cells and parks on cardiolipin, the fat that holds the inner mitochondrial membrane together. In September 2025 it became the first mitochondria-targeted drug ever approved by the FDA โ for one ultra-rare disease, at 40 mg a day.
Includes 10ร sterile insulin syringes + 1 vial of bacteriostatic water, free with your order.
Complete your kit
For research and educational use only. Not for human or veterinary consumption.
What has actually been shown:
- It goes where the energy is made. SS-31 binds cardiolipin on the inner mitochondrial membrane, which keeps the folds of that membrane intact and the respiratory machinery working together. It gets into cells easily and concentrates in mitochondria, which is what made it interesting in the first place.
- It improved muscle strength in Barth syndrome โ a genetic disease where cardiolipin itself is faulty. That's the basis of the 2025 FDA approval, at 40 mg daily.
- Old mice got measurably fitter. Eight weeks reversed part of the age-related loss in heart function and muscle fatigue resistance, and slowed frailty.
- One infusion briefly raised ATP capacity in older people's muscle โ gone a week later, and with no change in how quickly the muscle tired.
What people using it report:
- Steadier energy and less afternoon fatigue, usually described within the first one to two weeks
- Better tolerance of hard training sessions and quicker bounce-back
- Less "brain fog" โ the most subjective report, and the hardest to separate from expectation
- Commonly stacked with MOTS-c and NAD+ as a "mitochondrial" protocol
SS-31 vs MTS-C (MOTS-c) โ not the same thing
| SS-31 | MTS-C (MOTS-c) | |
|---|---|---|
| What it is | Synthetic 4-amino-acid peptide | 16-amino-acid peptide your mitochondria make naturally |
| Where it acts | Inside the mitochondrion, on the membrane | Signals outward, mainly to muscle, via AMPK |
| Idea | Repair the power plant | Tell the body to burn fuel like it trained |
| Human data | Approved drug, several large trials (mostly negative outside Barth) | No completed interventional human trial |
If your goal is metabolic โ insulin sensitivity, fat oxidation during a diet โ MTS-C is the one people use. SS-31 is about the mitochondria themselves.
It has not been shown to do anything in healthy people. Every human trial was in a disease, at 40 mg a day โ and outside Barth syndrome, the big ones missed their main goal:
- Mitochondrial myopathy (218 patients, 24 weeks): no improvement in walking distance or fatigue.
- Heart failure (71 patients, 4 weeks): no change in heart size or pumping.
- Dry macular degeneration (176 patients, 48 weeks): primary endpoints missed, although a secondary photoreceptor measure looked better. A phase 3 is running.
The doses people use from vials like this are 20 to 40 times lower than any trial. Nobody has tested whether 1โ2 mg a day does anything. We're not going to pretend otherwise.
It is not a stimulant and it is not a fat burner. If you feel a jolt within an hour, that isn't the peptide.
It does not reverse ageing. The best ageing study (in mice) improved function but did not change biological-age markers at all.
This is the research compound, not the approved medicine. Forzinity is a sterile, ready-made 80 mg/mL solution dispensed through specialist pharmacies.
Very common โ expect this one: injection site reactions. In the FDA's controlled trial, every patient on SS-31 had redness at the site, two-thirds had itching and hardening, and three-quarters had pain. It's not contamination and not an infection: SS-31 directly triggers the mast cells in your skin to release histamine. Most reactions are mild and fade within days. Rotate sites every day.
Less common:
- Bruising or hives limited to the injection site
- Headache, mild nausea, dizziness โ reported by users and prescribers, usually in the first days
- Raised eosinophils (a white-cell type) on blood tests after 30+ days of use, which returned to normal over time in trial patients
- In the 24-week myopathy trial, 7.3% stopped because of side effects, versus 1.8% on placebo
Stop and see a doctor:
- Hives or itching that spreads beyond the injection site, swelling of the lips, face or throat, wheezing or a persistent cough โ serious allergic reactions needing emergency treatment have been reported with the approved drug, from minutes to months after starting
- Faintness or a drop in blood pressure after an injection
- A site that keeps getting bigger, hot and painful after 2โ3 days, or weeps โ possible infection
๐ Don't use it if you have severe kidney disease (it's cleared by the kidneys and builds up), a mast cell disorder or a history of serious drug allergies, or if you're pregnant or breastfeeding.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
10 mg vial + 1 mL bacteriostatic water = 10 mg/mL
| Dose | Volume | Units (U-100) |
|---|---|---|
| 0.5 mg | 0.05 mL | 5 |
| 1 mg | 0.10 mL | 10 |
| 2 mg | 0.20 mL | 20 |
| 5 mg | 0.50 mL | 50 |
Inject the water slowly down the inside wall of the vial. Swirl gently, never shake. It should dissolve to a clear, colourless solution. Refrigerate at 2โ8 ยฐC and use within 4 weeks.
For scale: the approved 40 mg daily dose would be four full vials, every day.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
โ ๏ธ Read this before you order โ vial size and cost
The approved dose is 40 mg once daily. This 10 mg vial is a quarter of one clinical dose. Nobody runs SS-31 at trial doses from research vials, and nobody knows whether the much lower community doses work. If you buy it, buy it knowing that. Message us on WhatsApp first if you're unsure โ we'll tell you honestly whether it fits what you're after.
Community protocol: 1 mg once daily, subcutaneous, mornings. Abdomen or thigh, a different spot every day. After the first week, if your skin is tolerating it, some move to 2 mg.
| Protocol | Units (U-100) | One vial lasts | 4 weeks needs |
|---|---|---|---|
| 1 mg daily | 10 | 10 days | 3 vials |
| 2 mg daily | 20 | 5 days | 6 vials |
| 5 mg twice weekly (some clinics) | 50 | 1 week | 4 vials |
Cycle: 4โ8 weeks, then at least 4 weeks off. Daily dosing makes more pharmacological sense than twice weekly โ SS-31 clears from the blood within a day or two.
To reduce site reactions: never inject the same spot twice in a week, skip any area that's still red or hard, and let the pen or syringe reach room temperature first. A cold pack afterwards eases the sting. The approved label says reactions can be treated with an antihistamine or a topical steroid cream โ ask a pharmacist which.
- 1ร SS-31 ยท 10 mg
- 10ร sterile insulin syringes (free)
- 1ร bacteriostatic water vial (free)
- Compound Guide โ printed, included free
This is the only compound in our catalog that is now an approved medicine for its own mechanism. FDA accelerated approval came on 19 September 2025 (as Forzinity), for muscle strength in Barth syndrome patients weighing at least 30 kg โ based on knee-extension strength, with a confirmatory trial required to keep the approval. It is not approved in the EU or anywhere else as of late 2026.
The approval rests on 12 patients in a crossover trial that missed its primary endpoints, followed by an open-label extension in which 8 patients reached three years with sustained gains. In larger trials outside Barth syndrome โ mitochondrial myopathy, heart failure, dry AMD โ the primary endpoints were not met. The ageing evidence is from mice plus one single-infusion study in older adults. There is no trial of SS-31 in healthy people, and no data at all at the 1โ5 mg doses used from research vials. What we supply is research-grade material, not the approved product.
Athletes: SS-31 is not named on the 2026 WADA Prohibited List, and since its FDA approval it no longer falls under S0 (non-approved substances). That is not a clearance โ check with your anti-doping organisation before using it.
- Szeto, British Journal of Pharmacology, 2014 โ review of how SS-31 binds cardiolipin and protects mitochondrial energy production
- FDA, FORZINITY prescribing information, 2025 โ accelerated approval for Barth syndrome at 40 mg daily; injection site reactions in every treated patient in the controlled trial
- Reid Thompson et al., Genetics in Medicine, 2021 โ TAZPOWER: no benefit in the 12-week randomised phase; 6-minute walk +95.9 m at 36 weeks open-label in Barth syndrome
- Thompson et al., Genetics in Medicine, 2024 โ 168-week open-label extension: 8 patients, sustained walk-test and cardiac improvements
- Karaa et al., Neurology, 2023 โ MMPOWER-3: 218 adults, 40 mg/day for 24 weeks, failed both primary endpoints in primary mitochondrial myopathy
- Butler et al., Journal of Cardiac Failure, 2020 โ PROGRESS-HF: 71 heart failure patients, no change in heart volumes vs placebo
- Ehlers et al., Ophthalmology Science, 2025 โ ReCLAIM-2: 176 patients with dry AMD, primary endpoints missed, slower photoreceptor loss on a secondary measure
- Roshanravan et al., PLoS One, 2021 โ single IV infusion in 39 older adults briefly raised muscle ATP capacity; gone by day 7
- Mitchell et al., Aging Cell, 2025 โ 8 weeks in old mice reduced frailty and improved heart and muscle function, without changing epigenetic age
Every peptide batch we sell is tested by Janoshik Analytical, an independent laboratory. Every vial carries an internal AVERON batch code identifying the lot received; each lot is linked to its published Janoshik report. The report carries the manufacturer's submission/task number, not the AVERON code. Ask us or our driver which report covers your code and open it on the laboratory's own website before paying. In our own-driver zone, the team shows you the vial and the report for that batch before payment.
A lab report handed to you by a seller and a lab report you can verify yourself are not the same thing. That's why we publish ours.
View COA on Janoshik








